Outcome of Board Meeting GVK Power & Infrastructure Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. GVK Power & Infrastructure Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Outcome of Board Meeting GVK Power & Infrastructure Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. GVK Power & Infrastructure Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Company Update Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to submit herewith the Press Release issued by the Company in connection with the Audited Financial Results for the quarter and financial year ended March 31, 2026. We request you to kindly take this on record and make the enclosed presentation available to the public through the BSE portal. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Di
Company Update Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to submit herewith the Press Release issued by the Company in connection with the Audited Financial Results for the quarter and financial year ended March 31, 2026. We request you to kindly take this on record and make the enclosed presentation available to the public through the BSE portal. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Di
Company Update We would like to inform you that the Board of Directors of the Company''s material wholly owned subsidiary, Panacea Biotec Pharma Ltd., has in its meeting held today i.e. 29.05.2026 , inter-alia, approved the appointment / re-appointment of directors. Intimation with requisite details is enclosed herewith. We would like to inform you that the Board of Directors of the Company''s material wholly owned subsidiary, Panacea Biotec Pharma Ltd., has in its meeting held today i.e. 2
Company Update We would like to inform you that the Board of Directors of the Company''s material wholly owned subsidiary, Panacea Biotec Pharma Ltd., has in its meeting held today i.e. 29.05.2026 , inter-alia, approved the appointment / re-appointment of directors. Intimation with requisite details is enclosed herewith. We would like to inform you that the Board of Directors of the Company''s material wholly owned subsidiary, Panacea Biotec Pharma Ltd., has in its meeting held today i.e. 2
Company Update The requirement to submit the Statement of Deviation(s) or Variation(s) under Regulation 32(1) is Not Applicable to the company for the quarter ended 31st March 2026. The requirement to submit the Statement of Deviation(s) or Variation(s) under Regulation 32(1) is Not Applicable to the company for the quarter ended 31st March 2026.
Company Update The requirement to submit the Statement of Deviation(s) or Variation(s) under Regulation 32(1) is Not Applicable to the company for the quarter ended 31st March 2026. The requirement to submit the Statement of Deviation(s) or Variation(s) under Regulation 32(1) is Not Applicable to the company for the quarter ended 31st March 2026.
Outcome of Board Meeting Abhishek Corporation Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. Abhishek Corporation Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Outcome of Board Meeting Abhishek Corporation Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. Abhishek Corporation Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Corp Action Pursuant tom Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we write to inform you that the Board of Directors at their Meeting held on 29.05.2026 have recommended a dividend of Rs.10/- (10%) for the year ended 31.03.2026. Pursuant tom Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we write to inform you that the Board of Directors at their Meeting held on 29.05.2026 have recommended
Corp Action Pursuant tom Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we write to inform you that the Board of Directors at their Meeting held on 29.05.2026 have recommended a dividend of Rs.10/- (10%) for the year ended 31.03.2026. Pursuant tom Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we write to inform you that the Board of Directors at their Meeting held on 29.05.2026 have recommended
NSE & BSE filings, earnings, insider trades, and smart volume alerts — on WhatsApp or Telegram. No separate app to install.